For the nine months ended September 30, 2026, Ionis Pharmaceuticals reported total revenue of $756.8 million, a slight increase from $740.4 million in the prior year, driven by higher commercial product sales. However, the company's net loss widened significantly to $317.1 million compared to $152.0 million in 2025, primarily due to a substantial increase in selling, general, and administrative expenses.
Ionis Pharmaceuticals reported Q3 2026 total revenue of $243 million, a 55% increase year-over-year, driven by commercial revenue and R&D partnerships. The company lowered its 2026 product sales guidance for TRYNGOLZA due to a slower-than-expected launch ramp in the sHTG population, while reaffirming total revenue and cash guidance. Ionis ended the quarter with $1.9 billion in cash and short-term investments.
Term
Q3 2026
“TRYNGOLZA, our first launch in a large indication, represents a new treatment paradigm for the underserved sHTG population. While initial sales progress has been more gradual than anticipated, we are encouraged by the underlying launch fundamentals. Importantly, we have identified clear opportunities to improve performance, and we remain confident in TRYNGOLZA's long-term growth potential.”
Brett P. Monia, Ph.D., chief executive officer of Ionis
“In the third quarter, we generated higher quarter-over-quarter commercial revenue and substantial R&D revenue from partnered medicines while continuing to invest in our innovative wholly owned pipeline. Our commercial revenue growth was driven by DAWNZERA, which continues to gain momentum, supporting our confidence in achieving full-year DAWNZERA product sales guidance.”
Elizabeth L. Hougen, chief financial officer of Ionis